SOVREMENNAYA PEDIATRIYA.2016.5(77):102-106; doi10.15574/SP.2016.77.102 

Experience of the use of Urolesan^® preparation in children with chronic complicated pyelonephritis and secondary hyperoxaluria 

Kushnirenko S. V., Mordovets E. M., Tikhonenko N. A., Markotenko O. O., Gorokhovskaya T. A., Vinogradova T. N.

Shupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine

Kyiv City Children's Clinical Hospital №1, Ukraine

Objective — evaluation of the therapeutic and prophylactic potential of the Urolesan^® preparation in children with chronic complicated pyelonephritis and secondary hyperoxaluria.

Patients and methods. A total of 63 children were under observation. Patients of the group I (n=32) had received oral syrup Urolesan^® during the month, starting at the same time with the step-down antibiotic therapy (10 days) under inpatient treatment and continue with the preventive dose of furasidin under outpatient treatment. Patients of the group II (n=31) had received step-down antibacterial therapy (10 days) under inpatient treatment, and only prophylactic dose of furasidin during the outpatient treatment. The duration of treatment for each patient was one month. The total duration of the study for all patients was six months.

Results. The high efficiency of the treatment with additional use of the Urolesan^® preparation registered in 84.4% of patients by terms of the elimination of microbial-inflammatory processes and in 78.1% of patients by normalization of the pH and the excretion of oxalate in the urine, as well as by positive dynamics of the level of lithemia and uricosuria. The urological antiseptic action of Urolesan^® and potentiation of antibacterial effect in combination with the step-down therapy and prophylactic treatment as under inpatient so under the outpatient stage of treatment are provided.

Conclusions. Obtained results allow recommending Urolesan^® preparation for the treatment of complicated urinary tract infections in children.

Key words: chronic complicated pyelonephritis, secondary hyperoxaluria, children Urolesan^®.

REFERENCES

1. Ivanov DD, Kushnirenko SV. 2015. Infektsii sechovykh shliakhiv u praktytsi simeinoho likaria. Simeina medytsyna. 2: 46—50.

2. Ivanov DD, Korzh OM. 2014. Nefrolohiia v praktytsi simeinoho likaria. D, Vydavets Zaslavskyi: 464.

3. Kushnirenko SV. 2014. Krystalurii v praktytsi simeinoho likaria. Simeina medytsyna. 6: 36—38.

4. Protokol likuvannia ditei z infektsiiamy sechovoi systemy i tubuloin-terstytsialnym nefrytom. Nakaz MOZ Ukrainy № 627 vid 03.11.08. http://www.moz.gov.ua.

5. Ivanov DD, Vozianov SO, Kushnirenko SV ta in. 2014. Sechokamiana khvoroba, dysmetabolichna nefropatiia, krystaluriia. Metodychni rekomendatsii. Kyiv: 36.

6. Brandstrom P, Hansson S. 2015. Long-term, low-dose prophylaxis against urinary tract infections in young children. Pediatric Nephrology. 30: 425—432. http://dx.doi.org/10.1007/s00467-014-2854-z; PMid:24906665

7. Guidelines on Urological Infections. European Association of Urology, 2015.

8. Megged O. 2014. Staphylococcus aureus urinary tract infections in children are associated with urinary tract abnormalities and vesico-ureteral reflux. Pediatr Nephrol. 29: 269—272. http://dx.doi.org/10.1007/s00467-013-2655-9; PMid:24165967

9. Olorunmola FO, Kolawole DO, Lamikanra A. 2013. Antibiotic resistance and virulence properties in Escherichia coli strains from cases of urinary tract infections. Afr J Infect Dis. 7: 1—7. PMid:24381720 PMCid:PMC3647523

10. Carpenter MA, Hoberman A, Mattoo TK et al. 2013. The RIVUR trial: profile and baseline clinical associations of children with vesicoureteral reflux. Pediatrics. 132: 34—45. http://dx.doi.org/10.1542/peds.2012-2301; PMid:23753091 PMCid:PMC3691529